Your Source for Venture Capital and Private Equity Financings

Neurona Therapeutics Secures $41.5M

2021-06-22
SAN FRANCISCO, CA, Neurona Therapeutics today announced the successful completion of a $41.5 million financing.
Neurona Therapeutics, a biotherapeutics company developing neural cell therapies for the treatment of chronic neurological disorders, today announced the successful completion of a $41.5 million financing. Proceeds from the financing will be used to advance the company's pipeline of wholly-owned, off-the-shelf cell therapies for multiple indications, including a Phase 1/2a clinical study planned to launch later this year for its lead product, NRTX-1001, an inhibitory neuronal cell therapeutic, for the treatment of chronic focal epilepsy.

The financing was co-led by new investor UCB Ventures and current investor The Column Group. Other new investors included, Sphera Fund Management, Alexandria Venture Investments, and Ironfire Ventures.

Neurona's neural cell therapies have single-dose curative potential. Based on a novel neural cell lineage pioneered by the company's scientific founders, Neurona has built a robust regenerative platform and is developing neuronal, glial, and gene-edited cell therapy candidates that provide long-term repair of dysfunctional neural networks for multiple neurological disorders.
(c) by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors